Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

shutterstock_232245868

Amgen and AstraZeneca’s experimental drug cuts asthma exacerbations by up to 71%

September 7, 2017 Research and Development Amgen, AstraZeneca, MedImmune, asthma, pharma, pharmaceutical, tezepelumab

An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca’s global biologics and research division, MedImmune, has met its primary …
News
astrazeneca-sign

AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals

September 7, 2017 Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial

AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …
News

FDA halts trial after first CAR T-associated patient death

September 6, 2017 Research and Development CAR T, CAR-T, Cancer, FDA, cellectis, leukaemia, patient death, pharma, pharmaceutical

French clinical-stage biopharma firm Cellectis has received an order from the FDA to halt its study of CAR T therapy …
News
novo_flag

Novo Nordisk settles lawsuit over illegal marketing practices for $58.7 million

September 6, 2017 Research and Development, Sales and Marketing FDA, Novo Nordisk, US, US Justice Department, Victoza, diabetes, pharma, pharmaceutical

Novo Nordisk has resolved a probe by the US Justice Department which accused the Danish drugmaker of illegal marketing activities …
News

Anti-HIV drug PrEP proves safety in gay and bisexual adolescents

September 6, 2017 Research and Development Gilead, HIV, Pharamceuticals, PrEP, Truvada, health, medicine, pharma

A new study has found that pre-exposure prophylaxis (PrEP) drugs such as Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate), which pre-emptively protects …
News
shutterstock_38078521

Real-world data prove efficacy of Eisai and Bial’s epilepsy treatment

September 6, 2017 Research and Development Bial, Eisai, Zebinix, epilepsy, pharma

Bial and Eisai have released real-world data which support the efficacy of Zebinix (eslicarbazepine acetate) in the treatment of partial-onset …
News
narasimhan_2

Novartis exec designated as new CEO after Jimenez announces retirement

September 5, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, a, joe jimenez, phar, pharma, pharmaceuticals

Novartis has announced that its Chief Executive, Joe Jimenez, is set to retire next year. In his place, Vasant Narasimhan …
Appointment

Takeda’s Ninlaro knocked back by NICE for second time

September 5, 2017 Research and Development, Sales and Marketing Ninlaro, Takeda, biotech, drugs, pharma, pharmaceutical

NICE has revealed that the outcome of its consultation process for Ninlaro (ixazomib), Takeda’s treatment for relapsed or refractory multiple …
News
novartis_side_building

Novartis celebrates success of Gilenya in paediatric multiple sclerosis

September 5, 2017 Manufacturing and Production, Research and Development MS, Novartis, gilenya, health, multiple sclerosis, pharma, pharmaceuticals

Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod) , finding that …
News
asthma

Asthma drugs reduce Parkinson’s risk by 50%, decade-long study finds

September 5, 2017 Manufacturing and Production, Research and Development Parkinson's, Parkinson's disease, asthma, pharma, pharmaceuticals, salbutamol

A study from the Department of Global Public Health and Primary Care at the University of Bergen (UiB) in Norway …
News
heart-2338154_960_720

12% of the UK have hearts ten years older than they are, Public Health England finds

September 4, 2017 Research and Development, Sales and Marketing British Heart Foundation, Public Health England, cardiovascular disease, heart attack, heart health, stroke

New findings from Public Health England (PHE)’s Heart Age Test indicate that around 10% of men in the UK are …
News
gavel

Patently problematic? The impact of the Eli Lilly/Actavis intellectual property battle

September 4, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Eli Lilly, biotech, drugs, pemetrexed, pharma, pharmaceutical

The UK Supreme Court has sent shockwaves through the intellectual property world with its recent decision on Eli Lilly v …
Feature
entrance_takeda_i020_v1

Takeda partners up to develop “next generation” CAR T solid tumour therapy

September 4, 2017 Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, Noile-Immune, Takeda, pharma, pharmaceuticals

Takeda is set to partner with Noile-Immune Biotech in the development of a “next generation” chimeric antigen receptor T-cell (CAR …
News

Sanofi backs out of controversial Zika vaccine project

September 4, 2017 Research and Development, Sales and Marketing Sanofi, US, Vaccine, Zika, biotech, drugs, pharma, pharmaceutical

Sanofi’s development of a Zika vaccine, alongside the US’s Biomedical Advanced Research and Development Authority (BARDA), has hit the headlines …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 1, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Trump, drugs, health, life sciences, medicine, pharma, pharmaceutical, top ten

This week saw the news of a breakthrough in bispecific antibody production and Merck KGaA finally secured approval for its …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026